Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
anabolic steroid
androgen ester synthetic androgen |
| gptkbp:ATCCode |
G03BA03
|
| gptkbp:brand |
gptkb:Android
Metandren Oreton Methyl Testred |
| gptkbp:CASNumber |
58-18-4
|
| gptkbp:chemicalFormula |
C20H30O2
|
| gptkbp:contraindication |
gptkb:liver_disease
prostate cancer pregnancy breast cancer in men |
| gptkbp:derivedFrom |
testosterone
|
| gptkbp:discoveredBy |
1935
|
| gptkbp:eliminationHalfLife |
2.5–3.5 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:first_marketed |
1936
|
| https://www.w3.org/2000/01/rdf-schema#label |
methyltestosterone
|
| gptkbp:IUPACName |
17β-hydroxy-17α-methylandrost-4-en-3-one
|
| gptkbp:KEGGID |
gptkb:D00497
|
| gptkbp:legalStatus |
Schedule III controlled substance
|
| gptkbp:medicalUse |
treatment of breast cancer in women
treatment of delayed puberty in boys treatment of male hypogonadism |
| gptkbp:MeSH_ID |
D008767
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecular_structure_modification |
17α-methyl group
|
| gptkbp:molecularWeight |
302.451 g/mol
|
| gptkbp:pregnancyCategory |
X
|
| gptkbp:PubChem_CID |
6281
6046 CHEMBL1200396 DB06710 |
| gptkbp:relatedTo |
gptkb:nandrolone
gptkb:oxandrolone gptkb:stanozolol testosterone |
| gptkbp:routeOfAdministration |
oral
sublingual buccal |
| gptkbp:sideEffect |
hair loss
acne liver toxicity virilization increased aggression |
| gptkbp:synonym |
MT
17α-methyltestosterone methylandrostenolone |
| gptkbp:UNII |
70IYKD43PW
|
| gptkbp:bfsParent |
gptkb:M1T
|
| gptkbp:bfsLayer |
7
|